High bone density due to a mutation in LDL-receptor-related protein 5.

BACKGROUND Osteoporosis is a major public health problem of largely unknown cause. Loss-of-function mutations in the gene for low-density lipoprotein receptor-related protein 5 (LRP5), which acts in the Wnt signaling pathway, have been shown to cause osteoporosis-pseudoglioma. METHODS We performed genetic and biochemical analyses of a kindred with an autosomal dominant syndrome characterized by high bone density, a wide and deep mandible, and torus palatinus. RESULTS Genetic analysis revealed linkage of the syndrome to chromosome 11q12-13 (odds of linkage, >1 million to 1), an interval that contains LRP5. Affected members of the kindred had a mutation in this gene, with valine substituted for glycine at codon 171 (LRP5V171). This mutation segregated with the trait in the family and was absent in control subjects. The normal glycine lies in a so-called propeller motif that is highly conserved from fruit flies to humans. Markers of bone resorption were normal in the affected subjects, whereas markers of bone formation such as osteocalcin were markedly elevated. Levels of fibronectin, a known target of signaling by Wnt, a developmental protein, were also elevated. In vitro studies showed that the normal inhibition of Wnt signaling by another protein, Dickkopf-1 (Dkk-1), was defective in the presence of LRP5V171 and that this resulted in increased signaling due to unopposed Wnt activity. CONCLUSIONS The LRP5V171 mutation causes high bone density, with a thickened mandible and torus palatinus, by impairing the action of a normal antagonist of the Wnt pathway and thus increasing Wnt signaling. These findings demonstrate the role of altered LRP5 function in high bone mass and point to Dkk as a potential target for the prevention or treatment of osteoporosis.

[1]  D. Weaver,et al.  Bone mineral density and laboratory evaluation of a type II autosomal dominant osteopetrosis carrier. , 1999, American journal of medical genetics.

[2]  Susan R. Johnson,et al.  Osteoporosis prevention, diagnosis, and therapy. , 2001, JAMA.

[3]  M. Gelman Autosomal dominant osteosclerosis. , 1977, Radiology.

[4]  M. Bia,et al.  Etiology of hypercalcemia in hemodialysis patients on calcium carbonate therapy. , 1990, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[5]  D. Weaver,et al.  Molecular cloning and characterization of LR3, a novel LDL receptor family protein with mitogenic activity. , 1998, Biochemical and biophysical research communications.

[6]  Doris Wedlich,et al.  The Wnt/Wg Signal Transducer β-Catenin Controls Fibronectin Expression , 1999, Molecular and Cellular Biology.

[7]  L. Peltonen,et al.  Osteoporosis-pseudoglioma syndrome, a disorder affecting skeletal strength and vision, is assigned to chromosome region 11q12-13. , 1996, American journal of human genetics.

[8]  J. Ladenson,et al.  Creatine kinase brain isoenzyme (BB‐CK) presence in serum distinguishes osteopetroses among the sclerosing bone disorders , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[9]  Daniel L. Koller,et al.  Linkage of a QTL Contributing to Normal Variation in Bone Mineral Density to Chromosome 11q12–13 , 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[10]  E. Haan,et al.  Neurological involvement in Worth type endosteal hyperostosis: report of a family. , 1994, American journal of medical genetics.

[11]  Y. Omori,et al.  Idiopathic osteosclerosis. A report of 6 related cases. , 1968, Radiology.

[12]  J. Kerstetter,et al.  Increased circulating concentrations of parathyroid hormone in healthy, young women consuming a protein-restricted diet. , 1997, The American journal of clinical nutrition.

[13]  V. Sheffield,et al.  Human autosomal recessive osteopetrosis maps to 11q13, a position predicted by comparative mapping of the murine osteosclerosis (oc) mutation. , 1998, Human molecular genetics.

[14]  H. Verhaar,et al.  Comparison of the action of 17 beta-estradiol and progestins with insulin-like growth factors-I/-II and transforming growth factor-beta 1 on the growth of normal adult human bone-forming cells. , 1995, Maturitas.

[15]  R. Owen Van Buchem's disease (hyperostosis corticalis generalisata) , 1976, The British journal of radiology.

[16]  M. Järvinen,et al.  Epidemiology of Osteoporotic Pelvic Fractures in Elderly People in Finland: Sharp Increase in 1970–1997 and Alarming Projections for the New Millennium , 2000, Osteoporosis International.

[17]  K. Insogna,et al.  Parathyroid hormone increases circulating levels of fibronectin in vivo: modulating effect of ovariectomy. , 1997, Endocrinology.

[18]  Worth Hm,et al.  Hyperostosis corticalis generalisata congenita. , 1966 .

[19]  Stuart A. Aaronson,et al.  Novel mechanism of Wnt signalling inhibition mediated by Dickkopf-1 interaction with LRP6/Arrow , 2001, Nature Cell Biology.

[20]  R. Gorlin,et al.  Autosomal dominant osteosclerosis. , 1977, Radiology.

[21]  Mark L. Johnson,et al.  A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. , 2002, American journal of human genetics.

[22]  S. Cummings,et al.  Epidemiology and predictors of fractures associated with osteoporosis. , 1997, The American journal of medicine.

[23]  S. Teitelbaum,et al.  Bone resorption by osteoclasts. , 2000, Science.

[24]  E. Canalis,et al.  Glucocorticoid regulation of transforming growth factor beta 1 activity and binding in osteoblast-enriched cultures from fetal rat bone , 1991, Molecular and cellular biology.

[25]  Hyesung Jeon,et al.  Implications for familial hypercholesterolemia from the structure of the LDL receptor YWTD-EGF domain pair , 2001, Nature Structural Biology.

[26]  Mark L. Johnson,et al.  Linkage of a gene causing high bone mass to human chromosome 11 (11q12-13) , 1997, American journal of human genetics.

[27]  R. Marcus,et al.  Peak Bone Mass , 2000, Osteoporosis International.

[28]  J. Pérez-Vicente,et al.  Autosomal dominant endosteal hyperostosis , 1987, Clinical genetics.

[29]  K. Insogna,et al.  Estrogen modulates parathyroid hormone-induced fibronectin production in human and rat osteoblast-like cells. , 1994, Endocrinology.

[30]  T. Springer,et al.  An extracellular beta-propeller module predicted in lipoprotein and scavenger receptors, tyrosine kinases, epidermal growth factor precursor, and extracellular matrix components. , 1998, Journal of molecular biology.

[31]  A. Geiser,et al.  Decreased bone mass and bone elasticity in mice lacking the transforming growth factor-beta1 gene. , 1998, Bone.

[32]  C. Damsky,et al.  Fibronectin is a survival factor for differentiated osteoblasts. , 1998, Journal of cell science.

[33]  Miikka Vikkula,et al.  LDL Receptor-Related Protein 5 (LRP5) Affects Bone Accrual and Eye Development , 2001, Cell.

[34]  W M O'Fallon,et al.  Determinants of Reduced Survival Following Hip Fractures in Men , 1995, Clinical orthopaedics and related research.

[35]  Michael Kühl,et al.  Head inducer Dickkopf-1 is a ligand for Wnt coreceptor LRP6 , 2001, Current Biology.

[36]  S. Aota,et al.  Fibronectin regulates calvarial osteoblast differentiation. , 1996, Journal of cell science.

[37]  J Mao,et al.  Low-density lipoprotein receptor-related protein-5 binds to Axin and regulates the canonical Wnt signaling pathway. , 2001, Molecular cell.